ATE434762T1 - Biologischer marker für entzündung - Google Patents

Biologischer marker für entzündung

Info

Publication number
ATE434762T1
ATE434762T1 AT05812529T AT05812529T ATE434762T1 AT E434762 T1 ATE434762 T1 AT E434762T1 AT 05812529 T AT05812529 T AT 05812529T AT 05812529 T AT05812529 T AT 05812529T AT E434762 T1 ATE434762 T1 AT E434762T1
Authority
AT
Austria
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
AT05812529T
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Lea Madi
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE434762(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE434762T1 publication Critical patent/ATE434762T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05812529T 2004-12-02 2005-11-30 Biologischer marker für entzündung ATE434762T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001279 WO2006059327A1 (en) 2004-12-02 2005-11-30 A biological marker for inflammation

Publications (1)

Publication Number Publication Date
ATE434762T1 true ATE434762T1 (de) 2009-07-15

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05812529T ATE434762T1 (de) 2004-12-02 2005-11-30 Biologischer marker für entzündung
AT05813139T ATE402739T1 (de) 2004-12-02 2005-11-30 Behandlung von entzündungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05813139T ATE402739T1 (de) 2004-12-02 2005-11-30 Behandlung von entzündungen

Country Status (13)

Country Link
US (3) US20080056992A1 (de)
EP (2) EP1817589B1 (de)
JP (2) JP4842964B2 (de)
KR (2) KR20070100261A (de)
AT (2) ATE434762T1 (de)
AU (2) AU2005310873B2 (de)
BR (2) BRPI0518777A2 (de)
CA (2) CA2586773C (de)
DE (2) DE602005008639D1 (de)
DK (1) DK1817079T3 (de)
ES (2) ES2327435T3 (de)
MX (2) MX2007006500A (de)
WO (2) WO2006059327A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
AU2006321165B2 (en) 2005-11-30 2010-04-22 Can-Fite Biopharma Ltd. Use of A3 adenosine receptor agonist in osteoarthritis treatment
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
PT2137202T (pt) 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd Processo para a síntese de ib-meca
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
RU2012138043A (ru) * 2010-03-03 2014-04-10 Гавенмент Оф Зе Юсэй, Репрезентид Бай Зе Секретэри, Департмент Оф Хелс Энд Хьюман Сервисес Агонисты а3аr для лечения увеита
EP2583972B1 (de) * 2010-06-18 2018-04-18 Hayashibara Co., Ltd. Therapeutikum für entzündungskrankheiten mit adenosin-n1-oxid als wirkstoff
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985005031A1 (en) 1984-05-09 1985-11-21 The Australian National University A method for the modulation of the immune response
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
PT942740E (pt) 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
EP1554574A2 (de) * 2002-10-21 2005-07-20 Can-Fite Biopharma Ltd. Diagnostische marker für therapeutische behandlung
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
AU2003274648A1 (en) * 2002-10-22 2004-05-13 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a diseased state
WO2004045627A1 (en) * 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
NZ544367A (en) 2003-06-25 2009-12-24 Elan Pharm Inc Combination therapy involving methotrexate for treating rheumatoid arthritis
JP2007517019A (ja) 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法

Also Published As

Publication number Publication date
CA2586774A1 (en) 2006-06-08
CA2586773C (en) 2018-03-27
AU2005310873A1 (en) 2006-06-08
DE602005015135D1 (de) 2009-08-06
EP1817589A1 (de) 2007-08-15
AU2005310874A1 (en) 2006-06-08
ATE402739T1 (de) 2008-08-15
WO2006059328A1 (en) 2006-06-08
AU2005310874B2 (en) 2008-11-27
ES2309817T3 (es) 2008-12-16
ES2327435T3 (es) 2009-10-29
WO2006059327A1 (en) 2006-06-08
KR20070090222A (ko) 2007-09-05
EP1817079B1 (de) 2008-07-30
AU2005310873B2 (en) 2008-11-27
CA2586773A1 (en) 2006-06-08
BRPI0518777A2 (pt) 2008-12-09
KR20070100261A (ko) 2007-10-10
US20130345163A1 (en) 2013-12-26
US8541182B2 (en) 2013-09-24
JP2008522182A (ja) 2008-06-26
JP2008521883A (ja) 2008-06-26
JP4842964B2 (ja) 2011-12-21
EP1817589B1 (de) 2009-06-24
DK1817079T3 (da) 2008-11-17
MX2007006501A (es) 2007-07-13
MX2007006500A (es) 2007-07-13
DE602005008639D1 (de) 2008-09-11
US20100256084A1 (en) 2010-10-07
BRPI0518795A2 (pt) 2008-12-09
US20080056992A1 (en) 2008-03-06
EP1817079A1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
ATE434762T1 (de) Biologischer marker für entzündung
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE527544T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2011105466A (ru) Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
NZ619918A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008041953A3 (en) Dengue diagnosis and treatment
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
DE602007006672D1 (de) Testverfahren und kit zur vorhersage des implantationserfolgs bei unterstützter befruchtung
ATE548050T1 (de) Diagnoseverfahren
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
WO2007044622A8 (en) Use of mif and mif pathway agonists
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
WO2011113942A3 (en) Method for predicting the responsiveness to chemotherapy
DK1393078T3 (da) Fremgangsmåder til diagnosticering in vitro eller til overvågning af en sygdom involverende en inflammatorisk reaktion
BRPI0713380A2 (pt) Métodos para determinar in vitro a quantidade de ácidos nucleicos nucleares em pelo menos uma célula, e para diagnosticar e/ou prognosticar câncer em um indivíduo humano ou animal
RU2006142106A (ru) Способ оценки фертильных свойств эякулята
DK1996934T3 (da) Fremgangsmåde til at evaluere nyrefunktion i et kattedyr ved at måle ghrelinhomonniveauerne
EA201001340A1 (ru) Улучшенный аналитический способ для определения латентного гепатита с, его применения и соответствующий диагностический набор

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties